HIV

In a recap of his recent NPhA continuing pharmacy education presentation, Kenric B. Ware, PharmD, MBA, AAHIVP, discussed pharmacists’ role in addressing HIV stigma.

Kenric B. Ware, PharmD, MBA, AAHIVP, addresses the pharmacist’s role in addressing HIV stigma and providing public health services for patients with the virus.

With little evidence on vaccine coverage for people living with HIV, researchers explored pneumococcal vaccine rates between 2014 and 2023.

The FDA approves the Insti HIV Self Test, enabling rapid, accurate results in just one minute, enhancing access to HIV testing nationwide.

Among individuals with both diabetes and HIV, researchers determine patients’ adherence to comprehensive diabetes care interventions.

FDA approves Biktarvy for HIV treatment in patients not virologically suppressed, enhancing options for those restarting antiretroviral therapy.

Investigators find that the phase 2 trial supports the further development of MK-8527 as an HIV pre-exposure prophylaxis.

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.

The investigators of a study also found that patient satisfaction with long-acting injectable antiretroviral therapy was equally as high when comparing home and clinic administration.

Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.

Additional data shows that an investigational drug, given every 4 months with Apretude, kept viral levels suppressed for patients who were already on stable treatment.

These findings are shared as late-breaking data at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco, California.

A PDUFA target action date for the PrEP therapy has been set for June 19, 2025.

A tour of modern antiretroviral and pre-exposure prophylaxis therapies included the latest updates in HIV management and prevention.

In the most recent episode of Over the Counter, Jay Holloway, PharmD, AAHIVP, discussed advancements in HIV, especially regarding the role of pharmacists.

Jay Holloway, PharmD, AAHIVP, Pharmacist with the AIDS Healthcare Foundation, joined Drug Topics to discuss the role pharmacists play in providing care for people with HIV.

Jay Holloway, PharmD, AAHIVP, Pharmacist with the AIDS Healthcare Foundation, discussed the ongoing developments impacting patients with HIV and their prescription drugs.

Cassandra Esperant, PharmD, AAHIVP, discussed the ups and downs of her career journey as a clinical HIV pharmacist.

The data from PURPOSE 2 will be published in The New England Journal of Medicine.

Cassandra Esperant, PharmD, AAHIVP, leverages her expertise as a clinical pharmacist to advocate for the well-being of individuals with HIV.

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

The first-line B/F/TAF regiment was evaluated in Hispanic/Latino patients, as well as in those with chronic kidney disease.

Gilead said data from the study will support global regulatory filings that the company plans to begin by the end of the year.

Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.